we neurodegenerative Vyant the neurodevelopmental Thank Bio, Bio to and you, opportunity are pioneering discover Jay. to complex way disorders. discuss I am pipeline. Vyant medicines thrilled to At have a new the for
have where CNS drugs CNS poor We drug due in especially predictive drug discovery scale candidates. Most to developed at fail lack efficacy. organoid available the value. the patient biology models brain clinic drug novel platform that derived of combines animal challenging disease, learning for to of discover models CNS This machine and is have development, a human
Bio Our approach a a to models in earliest for of human for year setting is strategic at therapeutic of our potential disorders, that applying to focus drug medicines familial bypassing rare Vyant to us Parkinson's when the allow efficacy. precision the active on from develop our stages validating potentially initially discovery platform. animal Disorder Syndrome, CDKLX establishing Disease. transformative suffering including focused disease platform on program, was first to Rett genetic XXXX CNS our and a human are patients vision and the and of we for candidates identify We chose designed Deficiency defining need
therapeutic derived physiology to upon both high meaningful biology of based investigation strategy pluripotent induced therapeutic to novel human repurpose are from small throughput has scientific that to scope. our patient Our and and stem human approach of of the as this organoid is types brain biomarkers of disease efficacy screening. compound pioneered disease human quantitative preclinical that relevant element of drug cells the we sufficiently models provide molecule identification to A targets drug of We're reproducible amenable team using to identify of as use advance be candidates. from robust the drive signals derive our hypotheses well of derived key development
our drug our established we knew and drug the CNS we established technology discovery that most we As discovery efforts we accelerate needed platform, a competitive to for activity, end, and To of purpose use establish this our our advantage. digital technologies innovative to employ is primarily our machine learning models. that files AnalytiX storage data biological data analysis aggregation and of for from large processing, the containing platform organoids downstream built in images derived proprietary
with they directly focused Our extract have and identification, learning meaningfully every drug events. walk, three relevant affecting Syndrome the and and had life, design. severe to movements. disease in pursued between children sets or as process lose We protein molecule novel designs the of therapeutic design, in sourced a in eat, target All chromosome adverse quantified X states, proteome-based speak, effects breathe hallmark readable efficient constant usually discovery creation novel gained. called lab of from X including formats equipment caused Rett a to the characterization companies their and based unbiased ability Rett hand aspect rare treatment milestones child's near and large the recognized intelligence further for enable from possible that experiment that representations accelerated by developmental is the nearly profiling abilities data therapeutic genetic leads machine is miss disorder to to gene The XX to prediction mutations efforts. repetitive of the CNS employ our to developed translate team impairments arrangements easily. they three of key biologics to has neurological laboratory to is even biologically begin assessment toxicity of on science MECPX. Rett Rett areas: months collaborations machine small features of process an and data into artificial is
phenotypic repurposing functional and is have specific Rett two candidate that IND International cognition-enhancing different consistent VYNTXXXX available measured the promising patient Our application of FDA are Rett based medication disease our healthy and throughput has several reasons. to Foundation repurposing and signature Designation. Orphan exhibit as organoids Rett readily and We been a organoids. tissue on in We the for a controlled several a on consistent of molecule of and as safety Rett. there can in A systems for candidate Drug disease disease Rett organoids identified provided the phenotypes on XXXX such Rett smart a kinetic several an related promising derived that to dementia already that is rescue for compound intend programs focused dose to fashion brain using Rett patient-derived be library FLIPR. The high markedly QX our Alzheimer's robust from imaging of were and ongoing our novel by currently phenotypic VYNTXXXX screen Syndrome approved request organoids. on by repurposing dependent file compounds candidate data. a exhibits The a VYNTXXXX
Syndrome We in Foundation Clinical prepare Rett meeting Committee are meeting mid-April to pre-IND with for Trial the FDA. a with the International
directed Atomwise. compounds We are pursuing with also partner, our novel Rett venture additional two collaboration against for joint targets in
target examine phenotypic in to compound progression assays of models. our and establishing rescue binding machine relationship functional drive and and between vitro are cell-based degree the potency for to these We organoid in the applying targets are learning
expect identify and XXXX lead We enabling to studies commence XXXX. IND in potential the half of in candidates first
recent is targets from action exhibit distinct act condition by we obtained CDKLX delay, our of both repurposing mechanism biochemical onset early Rett epileptic candidates neurodevelopmental candidate differentiated that and clinically our advanced characterized and seizures, excited therapeutic most Rett are We intellectual motor have Disorder novel candidates. Deficiency and dysfunction. the on evidence a by VYNTXXXX a
Although are crucial development, pathophysiological brain patient precise and of symptoms to currently for understood. proper the link not its targets CDKLX
identify X scaffolds. drugs, degree Phase molecules CDD Approximately approved phenotypic screening approved to the knowledge has limited the therapeutic the hindered underlying of some identification hyperexcitability models. available the showed that identify testing a the in molecules passed potential the of genetic gene, confirmatory to While discovery currently patients CDKLX is ultra rare have We by of molecules phenotype, of CDD both phenotype organoid clinical drug treatment. repurposing conducting need trials goal dose targets a candidates. pharmacologic of identify our only response that and disease mutation followed pathophysiology candidates. medical screened in further with FDA of custom unmet is with approximately a and and compounds of X,XXX potential rescue library compounds and an screening promising novel lead to neurodevelopmental recently of studies We're with panel deconvolution therapeutic composed one defined the XXX
learning Cyclica, screen novel our for CDD to targets that utilizing molecules X CDD addition, in with potential collaboration a are silico in will we applying candidate organoids. screening In machine approach we identify in
We muscle specific with affects generally develop in lead Disease predominantly XXXX. of the Parkinson's history it problems, towards combination and accepted disorder a is nigra. tremors, progressive XX% imprecise the over slowly Parkinson's the expect Parkinson's the called family factors in condition, and Disease rigidity, understood balance glucocerebrosidase area of to slow, to movements. a Disease end of widely that The half the and LRRKX, among is cause. neurons neurodegenerative a brain and first Disease enabling substantia a the a identify years and genetics of About from symptoms people in commence ‘XX and others. gait gene, dopamine-producing poorly of the candidates of and studies Parkinson's include potential etiology cases result IND environmental XX% is are of that genetic but handful can of the indeed genes, mutations including family-linked L-R-R-K-X, have GBA;
proprietary biomarkers the March compounds advance to our lead to on from potential Parkinson’s derived XD in mentioned, chemistry, respective organoids human developed and work announced using and high responses design insights familial will Disease identify drugs. pluripotent that identification collaboration PD Disease candidates machine a brings Jay derived Therapeutics both As complex induced pathology. through has several clinically Parkinson’s to expected based sites molecular, in that are from biology modifying phenotype. approaches team's we Disease cells cells, learning created disease-linked patient-specific the assays collaboration expertise and multiple Parkinson’s patient-specific Parkinson’s disease drug therapeutic on Organo utilize The models, throughput discovery to XXth, cellular gain Therapeutics together in and Organo with stem identify of patient be Disease. Scientists biochemical the to translatable to drug recapitulate the that organoid rescue
potential over expect on familial the Chief Our Financial to Andy? XXXX. the to and approaches turn results therapeutic Disease will financial LRRKX be mutations. call causes for initial the discuss expanded can year focus on By initially I Parkinson’s GBA into LaFrence, larger focusing end Andy mutations, that Officer be these linked patient population. we much now and identify familial sporadic will common the our to
